Arizona State Retirement System boosted its holdings in FibroGen, Inc. (NASDAQ:FGEN – Get Rating) by 4.3% during the 4th quarter, Holdings Channel reports. The firm owned 25,129 shares of the biopharmaceutical company’s stock after acquiring an additional 1,043 shares during the period. Arizona State Retirement System’s holdings in FibroGen were worth $403,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. Franklin Street Advisors Inc. NC purchased a new position in shares of FibroGen in the 4th quarter worth about $160,000. TD Asset Management Inc purchased a new position in FibroGen in the fourth quarter valued at about $588,000. U.S. Capital Wealth Advisors LLC purchased a new position in FibroGen in the fourth quarter valued at about $54,000. ProShare Advisors LLC grew its position in shares of FibroGen by 8.5% during the 4th quarter. ProShare Advisors LLC now owns 19,025 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 1,497 shares during the period. Finally, State of New Jersey Common Pension Fund D purchased a new stake in shares of FibroGen during the 4th quarter worth approximately $2,669,000. Institutional investors own 76.89% of the company’s stock.
Insider Transactions at FibroGen
In related news, CEO Enrique A. Conterno sold 1,869 shares of the business’s stock in a transaction dated Monday, April 10th. The stock was sold at an average price of $19.52, for a total transaction of $36,482.88. Following the completion of the transaction, the chief executive officer now directly owns 382,999 shares in the company, valued at $7,476,140.48. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, CFO Juan Graham sold 2,749 shares of the firm’s stock in a transaction that occurred on Wednesday, March 8th. The shares were sold at an average price of $21.16, for a total value of $58,168.84. Following the sale, the chief financial officer now directly owns 70,213 shares of the company’s stock, valued at $1,485,707.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Enrique A. Conterno sold 1,869 shares of FibroGen stock in a transaction that occurred on Monday, April 10th. The shares were sold at an average price of $19.52, for a total transaction of $36,482.88. Following the sale, the chief executive officer now owns 382,999 shares of the company’s stock, valued at $7,476,140.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 115,931 shares of company stock valued at $2,358,203. 2.82% of the stock is currently owned by company insiders.
FibroGen Stock Down 0.4 %
FibroGen (NASDAQ:FGEN – Get Rating) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.05). FibroGen had a negative return on equity of 879.75% and a negative net margin of 264.63%. The firm had revenue of $36.16 million for the quarter, compared to the consensus estimate of $31.52 million. During the same period last year, the company posted ($0.68) EPS. The business’s revenue was down 40.6% on a year-over-year basis. On average, equities research analysts anticipate that FibroGen, Inc. will post -2.83 EPS for the current fiscal year.
Wall Street Analyst Weigh In
FGEN has been the subject of several research reports. Cowen increased their price objective on FibroGen from $15.00 to $25.00 and gave the company a “market perform” rating in a report on Tuesday, February 28th. The Goldman Sachs Group lifted their price objective on FibroGen from $9.00 to $16.00 and gave the stock a “sell” rating in a report on Tuesday, February 21st. William Blair raised shares of FibroGen from a “market perform” rating to an “outperform” rating in a report on Monday, January 30th. StockNews.com started coverage on shares of FibroGen in a research note on Thursday. They issued a “hold” rating for the company. Finally, Raymond James upgraded shares of FibroGen from a “market perform” rating to an “outperform” rating and set a $35.00 price target on the stock in a research note on Thursday, January 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, FibroGen presently has a consensus rating of “Hold” and an average target price of $23.40.
FibroGen Company Profile
FibroGen, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer.
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc. (NASDAQ:FGEN – Get Rating).
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.